Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of AVLX-144 in Healthy Volunteers
NCT04689035Phase 1Completed
- Sponsor
- Avilex Pharma
- Start
- Sep 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AVLX-144 in ischemic stroke and subarachnoid hemorrhage (SAH) (6 cohorts), sponsored by Avilex Pharma. Primary endpoint: Safety and tolerability of AVLX-144. Started Sep 2020; status: completed.
02
Drugs
AVLX-144
03
Conditions
ischemic strokesubarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT04689035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04689035.